Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in alzheimer's disease patients

Journal of Alzheimer's Disease

Volumn 30, Issue 4, 2012, Pages 745-749

  Albani, Diego ^a   Boneschi, Filippo Martinelli ^a   Biella, Gloria ^a   Giacalone, Giacomo ^b   Lupoli, Sara ^b   Clerici, Francesca ^c   Benussi, Luisa ^d   Ghidoni, Roberta ^d   Galimberti, Daniela ^e   Squitti, Rosanna ^d,f   Mariani, Stefania ^f   Confaloni, Annamaria ^g   Bruno, Giuseppe ^h   Mariani, Claudio ^c   Scarpini, Elio ^e   Binetti, Giuliano ^d   Magnani, Giuseppe ^b   Franceschi, Massimo ⁱ   Forloni, Gianluigi ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^g ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ IRCCS MULTIMEDICA   (Italy)

Author keywords

Alzheimer's disease; apolipoprotein E; CYP2D6; donepezil; pharmacogenetics; rs1080985

Indexed keywords

APOLIPOPROTEIN E; CYTOCHROME P450 2D6; DONEPEZIL;

ADULT; ALZHEIMER DISEASE; ARTICLE; DIGESTIVE SYSTEM DISEASE; DRUG EFFICACY; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVOUS DISEA; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84862982197     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-112123     Document Type: Article

References (25)

1. Giacobini E (2006) Cholinesterases in human brain: The effect of cholinesterase inhibitors on Alzheimer's disease and related disorders. In: The Brain Cholinergic System in Health and Disease, Giacobini E, Pepeu G, Eds. Informa Healthcare, London, pp. 235-264.
2. National Institute for Health and Clinical Excellence (2011) Technology appraisal TA217: Alzheimer's diseasedonepezil, galantamine, rivastigmine and memantine. http://guidance.nice.org.uk/TA217, Accessed on February 17, 2012.
3. Robinson DM, Keating GM (2006) Memantine: A review of its use in Alzheimer's disease. Drugs 66, 1515-1534.
4. Mayeux R (2010) Clinical practice. Early Alzheimer's disease. N Engl J Med 362, 2194-2201.
5. Cacabelos R (2008) Pharmacogenomics in Alzheimer's disease. Methods Mol Biol 448, 213-357.
6. Goldstein DB, Tate SK, Sisodiya SM (2003) Pharmacogenetics goes genomic. Nat Rev Genet 4, 937-947.
7. Daly AK (2010) Pharmacogenetics and human genetic polymorphisms. Biochem J 429, 435-449.
8. Tiseo PJ, Perdomo CA, Friedhoff LT (1998) Metabolism and elimination of 14C-donepezil in healthy volunteers: A singledose study. Br J Clin Pharmacol 1, 19-24.
9. Jann MW, Shirley KL, Small GW (2002) Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 41, 719-739.
10. Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD, Donepezil Study, Group (2001) Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 58, 427-433.
11. Sachse C, Brockmoller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60, 284-295.
12. The Human Cytochrome P450 (CYP) Allele Nomenclature Database, http://www.imm.ki.se/CYPalleles/cyp2d6.htm, Accessed November 10, 2011.
13. Varsaldi F, Miglio G, Scordo MG, Dahl ML, Villa LM, Biolcati A, Lombardi G (2006) Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients. Eur J Clin Pharmacol 62, 721-726.
14. Pilotto A, Franceschi M, D'Onofrio G, Bizzarro A, Mangialasche F, Cascavilla L, Paris F, Matera MG, Pilotto A, Daniele A, Mecocci P, Masullo C, Dallapiccola B, Seripa D (2009) Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology 73, 761-767.
15. Choi SH, Kim SY, Na HR, Kim BK, Yang DW, Kwon JC, Park MY (2008) Effect of ApoE genotype on response to donepezil in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 25, 445-450.
16. Blesa R, Aguilar M, Casanova JP, Boada M, Mart́?nez S, Alom J, de la Hoz CH, Sancho J, Ferńandez O, Gil-Neciga E, Masśo JF (2006) Relationship between the efficacy of rivastigmine and apolipoprotein E (epsilon4) in patients with mild to moderately severe Alzheimer disease. Alzheimer Dis Assoc Disord 20, 248-254.
17. Rigaud AS, Traykov L, Latour F, Couderc R, Moulin F, Forette F (2002) Presence of absence of least one epsilon 4 allele and gender are not predictive for theresponse to donepezil treatment in Alzheimer's disease. Pharmacogenetics 12, 415-420.
18. Santoro A, Siviero P, Minicuci N, Bellavista E, Mishto M, Olivieri F, Marchegiani F, Chiamenti AM, Benussi L, Ghidoni R, Nacmias B, Bagnoli S, Ginestroni A, Scarpino O, Feraco E, Gianni W, Cruciani G, Paganelli R, Di Iorio A, Scognamiglio M, Grimaldi LM, Gabelli C, Sorbi S, Binetti G, Crepaldi G, Franceschi C (2010) Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease:Aprospective, observational study. CNS Drugs 24, 163-176.
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
20. Raschetti R, Maggini M, Vanacore N (2003) Post-marketing studies: the Italian CRONOS project. Int J Geriatr Psychiatry 18, 962.
21. Zanger UM, Raimundo S, EichelbaumM(2004) Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedebergs Arch Pharmacol 369, 23-37.
22. Gaedigk A, Ryder DL, Bradford LD, Leeder JS (2003) CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584 G promoter polymorphism. Clin Chem 49, 1008-1011.
23. Chianella C, Gragnaniello D, Maisano Delser P,VisentiniMF, Sette E, Tola MR, Barbujani G, Fuselli S (2011) BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors. Eur J Clin Pharmacol 67, 1147-1157.
24. Savino M, Seripa D, Gallo AP, Garrubba M, D'Onofrio G, Bizzarro A, Paroni G, Paris F, Mecocci P, Masullo C, Pilotto A, Santini SA (2011) Effectiveness of a high-throughput genetic analysis in the identification of responders/non-responders to CYP2D6-metabolized drugs. Clin Lab 57, 887-893.
25. Seripa D, Bizzarro A, Pilotto A, D'onofrio G, Vecchione G, Gallo AP, Cascavilla L, Paris F, Grandone E, Mecocci P, Santini SA, Masullo C, Pilotto A (2011) Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease. Pharmacogenet Genomics 21, 225-230.